Asthma Week Australia: 1-7 September
Products are for professional/laboratory use only. Asthma is a serious respiratory condition affecting both children and adults across Australia and New Zealand. Over 2.5 million (about 1 in 9) Australians have asthma with more children than adults affected. There are over 400 asthma deaths each year in Australia alone.1
In New Zealand, over 590,000 people take medication for asthma – this includes an estimated 1 in 7 children and 1 in 8 adults. For children, asthma is one of the most common causes of hospital admissions.2
Asthma Week Australia raises awareness for people living with asthma. Asthma Australia provides prevention and health strategies to asthma suffers and highlights current research into treatment and developing a cure for asthma.3
l
What is asthma?
People with asthma have sensitive airways in their lungs. The airways may tighten, partially close up, swell inside, and make more mucus when faced with certain triggers. This makes it hard to breathe in, and even harder to breathe out.
The most common symptoms of asthma are:
- wheezing – a high-pitched sound coming from the chest while breathing
- a feeling of not being able to get enough air or being short of breath
- a feeling of tightness in the chest
- coughing.
Discover the connection between asthma and allergy and the benefits of ImmunoCAP
The majority of asthma patients suffer from allergies. ImmunoCAP blood testing helps you identify allergy triggers and develop an exposure reduction plan for improved patient well-being.
Asthma is a serious condition affected by underlying inhalant and food allergies
- Up to 7x higher risk for life-threatening asthma than in children with asthma alone
- Inhalant allergens add up and may push the patient over the symptom threshold
- Combination of allergy and viral infections increases the risk for severe asthma
d
f
Reducing allergen exposure improves asthma control
- Fewer symptoms, fewer hospital visits, and improved quality of life
ImmunoCAP helps you identify allergy triggers
- The most extensively studied and widely used sIgE blood test available
- Increases certainty in diagnosis from 50% to 90% when added to clinical history
- Can easily be performed irrespective of patient’s age, skin condition, medication, disease activity, and/or pregnancy status
ImmunoCAP provides true quantitative results for accurate decisions
Guidelines recommend IgE testing, such as ImmunoCAP, in addition to clinical history and physical exam for patients with asthma. (see references 21-23 in link to brochure).
f
d
References:
1. https://www.nationalasthma.org.au/
2. https://www.asthmafoundation.org.nz/your-health/living-with-asthma
3. https://asthma.org.au/get-involved/asthma-week/
